Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthopediatrics (KIDS) Other Non-Current Liabilities (2019 - 2025)

Orthopediatrics (KIDS) has disclosed Other Non-Current Liabilities for 7 consecutive years, with $9.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities rose 61.86% to $9.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.5 million, a 61.86% increase, with the full-year FY2025 number at $9.5 million, up 61.86% from a year prior.
  • Other Non-Current Liabilities was $9.5 million for Q4 2025 at Orthopediatrics, up from $7.7 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $31.5 million in Q1 2022 to a low of $292000.0 in Q2 2021.
  • A 5-year average of $5.9 million and a median of $2.6 million in 2022 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: plummeted 98.96% in 2021, then surged 9893.65% in 2022.
  • Orthopediatrics' Other Non-Current Liabilities stood at $28.9 million in 2021, then crashed by 89.69% to $3.0 million in 2022, then tumbled by 62.68% to $1.1 million in 2023, then skyrocketed by 429.86% to $5.9 million in 2024, then skyrocketed by 61.86% to $9.5 million in 2025.
  • Per Business Quant, the three most recent readings for KIDS's Other Non-Current Liabilities are $9.5 million (Q4 2025), $7.7 million (Q3 2025), and $8.7 million (Q2 2025).